DMRTA2

DMRTA2 is a DM-domain transcription factor that maintains neural progenitor identity and controls cortical patterning during telencephalon development. It directly binds the Hes1 locus to sustain Hes1 expression and promote progenitor cell cycle re-entry, while repressing Pax6 via interaction with the NuRD corepressor complex and Zfp423, thereby coordinating the balance between progenitor maintenance and neuronal differentiation (PMID:28655839, PMID:40541527). Loss of Dmrta2 in mouse causes hippocampal agenesis, loss of medial cortical structures, and choroid plexus defects leading to hydrocephalus, and a human DNA-binding mutation causes agenesis of the corpus callosum and pachygyria (PMID:23056351, PMID:40456611, PMID:40541527). Outside the nervous system, DMRTA2 stabilizes p53 by competitively displacing HSP90β, suppressing p53 ubiquitination and nuclear export in NSCLC cells, and directly binds the cdkn2c promoter during zebrafish spermatogenesis (PMID:40728966, PMID:23175770).

1. 2011 High

   Establishing DMRTA2 as a transcriptional regulator in telencephalic neurogenesis: it was unknown how dorsal telencephalic proneural gene expression was controlled, and forward genetics revealed that Dmrta2 represses her6 to permit neurogenin1 expression.

   Evidence Forward genetic screen (ha2 mutant) in zebrafish with epistatic and overexpression analyses

   PMID:22023386

   Open questions at the time

   • Mechanism of her6 repression (direct binding vs. indirect) not resolved
   • Mammalian conservation of this specific regulatory axis not tested
2. 2012 High

   Demonstrating that Dmrta2 is essential for early telencephalic patterning and is a Wnt-pathway effector: it was unknown whether Dmrta2 had a required developmental role, and null/conditional knockouts revealed severe medial cortical defects including hippocampal agenesis, with Dmrta2 positioned downstream of Wnt/β-catenin signaling.

   Evidence Null and Emx1-cre conditional KO mice, dominant-negative Tcf and stabilized β-catenin overexpression, histological and expression analysis

   PMID:23056351

   Open questions at the time

   • Direct Wnt-responsive elements in Dmrta2 locus not identified
   • Downstream transcriptional targets not yet defined genome-wide
3. 2013 Medium

   Identifying a direct transcriptional target outside the brain: it was unknown how Dmrta2 functioned in non-neural tissues, and promoter binding assays showed Dmrta2 directly binds the cdkn2c promoter to sustain its expression during spermatogenesis, requiring an intact DM-domain.

   Evidence In vitro DNA-binding assays, promoter mutagenesis, inducible dominant-negative transgenic (R106Q) in zebrafish testis

   PMID:23175770

   Open questions at the time

   • In vivo ChIP at the cdkn2c locus not performed
   • Functional consequence of cdkn2c loss on spermatogonial proliferation not directly tested
   • Single laboratory finding
4. 2017 High

   Defining the core progenitor-maintenance mechanism: it was unclear how Dmrta2 kept cortical progenitors cycling, and ChIP plus rescue experiments demonstrated that Dmrta2 directly binds and activates Hes1, whose re-expression rescues precocious neurogenesis in Dmrta2-null progenitors.

   Evidence ChIP in ESC-derived cortical progenitors, RNA-seq, Hes1 rescue in Emx1-cre conditional KO mouse

   PMID:28655839

   Open questions at the time

   • Whether Dmrta2 activates Hes1 alone or through co-activators not determined
   • Genome-wide direct binding landscape (ChIP-seq) not reported
5. 2024 Medium

   Revealing a cytoplasmic, non-transcriptional function: it was unknown whether DMRTA2 acted outside the nucleus, and co-immunoprecipitation showed DMRTA2 competitively displaces HSP90β from p53, blocking p53 ubiquitination and nuclear export, thereby stabilizing wild-type p53 and suppressing NSCLC proliferation.

   Evidence Reciprocal Co-IP, CRISPR KO, proliferation and apoptosis assays in NSCLC cell lines

   PMID:40728966

   Open questions at the time

   • Competition mechanism not validated with purified proteins or structural data
   • In vivo relevance in NSCLC models not demonstrated
   • Single laboratory finding
6. 2024 Medium

   Linking DMRTA2 to glioma stem cell biology: it was unknown whether DMRTA2 had a role in brain tumors, and knockdown impaired glioma sphere formation and stem cell-dependent angiogenesis, with DMRTA2 co-localizing with pericyte markers in GBM vasculature.

   Evidence shRNA knockdown, tumor sphere and tube formation assays, immunohistochemistry in human GBM

   PMID:38509074

   Open questions at the time

   • Direct molecular targets mediating glioma stem cell maintenance not identified
   • Pericyte-like role is correlative based on marker co-localization only
7. 2025 High

   Elucidating the repressive mechanism at Pax6 and linking a human mutation to cortical malformation: it was unknown how Dmrta2 repressed target genes, and experiments showed DNA-binding-dependent repression of the Pax6 enhancer via recruitment of the NuRD complex and Zfp423, while a human loss-of-binding mutation caused agenesis of the corpus callosum and pachygyria.

   Evidence Epistatic allelic series in mouse, P19 cell reporter assays, Co-IP for NuRD and Zfp423, human mutation functional characterization

   PMID:40541527

   Open questions at the time

   • NuRD complex recruitment not confirmed by ChIP at Pax6 locus in vivo
   • Whether Zfp423 is required for repression or has an independent role not resolved
8. 2025 Medium

   Establishing Dmrta2 as essential for choroid plexus integrity: it was unclear why Dmrta2 mutants develop hydrocephalus, and conditional deletion showed compromised choroid plexus cytoarchitecture and identified largely non-overlapping direct targets from the related factor Emx2.

   Evidence Conditional KO in medial telencephalic progenitors, gene expression analysis, interaction partner identification

   PMID:40456611

   Open questions at the time

   • Direct target genes in choroid plexus epithelium not individually validated
   • Mechanism of hydrocephalus (CSF overproduction vs. structural failure) not distinguished
9. 2026 Medium

   Confirming cell-autonomous progenitor maintenance in human cells: it was unknown whether the murine findings translated to human, and DMRTA2 KO in human cerebral organoids reduced radial glial cells, while KO in paediatric glioma cells enhanced neuronal differentiation and reduced tumorigenicity.

   Evidence CRISPR KO in hESC-derived cerebral organoids, scRNA-seq, loss-of-function in DHG-H3G34 glioma cells with tumorigenicity assays

   PMID:41844556

   Open questions at the time

   • Downstream transcriptional program in human RG cells not compared to mouse
   • Whether Hes1 activation is the conserved mechanism in human organoids not tested

• Genome-wide direct target identification via ChIP-seq in cortical progenitors and structural characterization of DMRTA2-NuRD interactions remain open, as does the mechanistic relationship between the nuclear transcriptional and cytoplasmic p53-stabilizing functions.
• No ChIP-seq defining genome-wide direct binding landscape
• No structural basis for NuRD or HSP90β interaction
• How nuclear vs. cytoplasmic functions are partitioned in different tissues is unknown